AMBROSE STUDY
30-DAy MorBidity and MoRtality Of CholecyStEctomy for Benign Gall Bladder Disease:
A TUGS Multinational Audit
STUDY OBJECTIVES
1) Evaluate 30-day morbidity and mortality of cholecystectomy for benign gall bladder diseases
2) Identify factors associated with 30-day morbidity and mortality of cholecystectomy for benign gall bladder diseases
INCLUSION CRITERIA
1) Study period: 1st January 2022 to 30th June 2022
​
2) Patient population: Adults (>/=18 years)
​
3) Intervention: elective and emergency laparoscopic, laparoscopic converted to open, or open cholecystectomy
4) Indication: benign gallbladder diseases diagnosed by clinical evaluation and gallbladder imaging – biliary colic, acute cholecystitis, choledocholithiasis, cholangitis and biliary pancreatitis, benign gall bladder polyp, acalculous cholecystitis, functional gall bladder disorders
5) Surgery performed anywhere in the world
EXCLUSION CRITERIA
1) Surgery outside the study period.
2) Patients <18 years of age.
3) Patients diagnosed intraoperatively or postoperatively with gallbladder cancer
4) Cholecystectomy as a part of another surgical procedure, e.g., pancreaticoduodenectomy or concurrent bariatric surgery
AUTHORSHIP CRITERIA
1 to 5 patient's complete dataset = 1 collaborative authorship
​
6 to 25 patients' complete dataset = 2 collaborative authorship
​
26 to 50 patients' complete dataset = 3 collaborative authorship
​
51 to 100 patients' complete dataset = 4 collaborative authorship
​
101 to 150 patients' complete dataset = 5 collaborative authorship
​
More than 150 patients' complete dataset = 1 named authorship
STUDY COORDINATOR
Geoffrey Wong
Please in case you have any question do not hesitate to ask the coordinator through the following email address: